ORYX Successfully Completes Phase I/IIa Trial to Treat HPV-Associated Cancers
ORYX announced the successful completion of a Phase I/IIa trial of the therapeutic vaccine VicOryx to treat p16INK4a-overexpressing HPV- (Human Papilloma Virus-) positive cancer patients in an open label, single center trial that included 26 patients. Inclusion criteria for the trial were a history of advanced HPV-positive cervical, vulvar, vaginal, penile, anal or head and neck cancers with diffuse expression of p16INK4a in the tumor, after standard therapy. After an initial interim safety assessment (10 patients), the primary endpoint was the induction of a cellular and/or humoral immune response against the therapeutic vaccine. Secondary endpoints were safety of immunization with VicOryx and tumor response according to RECIST. The vaccine was safe and induced humoral and cellular immune responses. Full data from the trial will be presented at upcoming scientific conferences.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Computer tool analyzes in detail genetic alterations in the genome of cancer cells - Developed by CSIC, CiberAMP allows establishing direct correlations between changes in the number of gene copies in tumor cells and their expression levels

CRISPR gene editing can cause hundreds of unintended mutations

New Potential Mechanism for Vision Loss Discovered - Visual cells may not simply die in some diseases, but are mechanically transported out of the retina beforehand
GVK Biosciences and Crelux set up Fragment-based Drug Discovery Platform to deliver Lead Molecules
List_of_important_publications_in_chemistry

Fight diabetes with exercise
